Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW Notifies of Changes to Precautions for Warfarin Potassium Preparations
December 15, 2011
- ELD Issues Fully Revised GL for Clinical Evaluation of Sleep Medications
December 14, 2011
- Dr Nakamura’s Premature Retirement to Affect “Drug Discovery Support Organization” Project
December 14, 2011
- Government Decides FY2012 Tax Revision Outline, to Extend R&D Tax Break System by 2 Years
December 13, 2011
- Ruling Coalition Prioritizes Economic Evaluation, Other Programs for 2012 Special Budget Quota
December 12, 2011
- MHLW Issues Notification to Change Japanese Pronunciation of “Rivaroxaban” to “Rivah-roxaban”
December 12, 2011
- MOF Asks MHLW for Add’l 10% Price Cut for Long-listed Drugs
December 12, 2011
- Price Cuts for Long-listed Drugs Will Not Promote Generic Drug Use: Korosho in Negotiations with MOF
December 10, 2011
- 11 APIs/26 Products to Return Premium for New Drug Development
December 9, 2011
- MHLW Minister Komiyama Calls on Opposition to Join Efforts to Consider Third-Party Organization
December 9, 2011
- US FDA Begins Review of Risks of Serious Bleeding in Patients Taking Dabigatran
December 9, 2011
- NHI Drug Pricing Subcommittee to Apply 80% Rule for Combination Drugs to Injectables, Topical Drugs
December 8, 2011
- Gov’t Tax Commission Decides to Extend Temporary R&D Tax Credits
December 8, 2011
- CSIMC Submits Opinion on Medical Fee Revision Including Views of Both Healthcare Providers and Medical Bill Payers
December 8, 2011
- MHLW Proposes Penalty for Companies that Receive Premium but Refuse Development Requests
December 8, 2011
- Payers, Care Providers Agree at CSIMC on Need for Price Cuts for Long-listed Drugs
December 8, 2011
- Representatives of Payers, Care Providers Argue Against Freeze on Prices of Essential Drugs
December 8, 2011
- 2010 Survey Shows OB/GYN Doctors, Surgeons Rise in Number
December 7, 2011
- MHLW Reform Plan Calls for “Reductions in NHI Prices of Original Drugs”
December 6, 2011
- Orphan Drug Designation Approved for Everolimus, Tafamidis Meglumine
December 6, 2011
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…